Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveys
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
OBJECTIVE: Flares of autoimmune rheumatic diseases (AIRDs) following COVID-19 vaccination are a particular concern in vaccine-hesitant individuals. Therefore, we investigated the incidence, predictors and patterns of flares following vaccination in individuals living with AIRDs, using global COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveys.
METHODS: The COVAD surveys were used to extract data on flare demographics, comorbidities, COVID-19 history, and vaccination details for patients with AIRDs. Flares following vaccination were identified as patient-reported (a), increased immunosuppression (b), clinical exacerbations (c) and worsening of PROMIS scores (d). We studied flare characteristics and used regression models to differentiate flares among various AIRDs.
RESULTS: Of 15 165 total responses, the incidence of flares in 3453 patients with AIRDs was 11.3%, 14.8%, 9.5% and 26.7% by definitions a-d, respectively. There was moderate agreement between patient-reported and immunosuppression-defined flares (K = 0.403, P = 0.022). Arthritis (61.6%) and fatigue (58.8%) were the most commonly reported symptoms. Self-reported flares were associated with higher comorbidities (P = 0.013), mental health disorders (MHDs) (P < 0.001) and autoimmune disease multimorbidity (AIDm) (P < 0.001).In regression analysis, the presence of AIDm [odds ratio (OR) = 1.4; 95% CI: 1.1, 1.7; P = 0.003), or a MHD (OR = 1.7; 95% CI: 1.1, 2.6; P = 0.007), or being a Moderna vaccine recipient (OR = 1.5; 95% CI: 1.09, 2.2; P = 0.014) were predictors of flares. Use of MMF (OR = 0.5; 95% CI: 0.3, 0.8; P = 0.009) and glucocorticoids (OR = 0.6; 95% CI: 0.5, 0.8; P = 0.003) were protective.A higher frequency of patients with AIRDs reported overall active disease post-vaccination compared with before vaccination (OR = 1.3; 95% CI: 1.1, 1.5; P < 0.001).
CONCLUSION: Flares occur in nearly 1 in 10 individuals with AIRDs after COVID vaccination; people with comorbidities (especially AIDm), MHDs and those receiving the Moderna vaccine are particularly vulnerable. Future avenues include exploring flare profiles and optimizing vaccine strategies for this group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 62(2023), 12 vom: 01. Dez., Seite 3838-3848 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jagtap, Kshitij [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmunity |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 20.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/kead144 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354664735 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354664735 | ||
| 003 | DE-627 | ||
| 005 | 20240320233029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/kead144 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM354664735 | ||
| 035 | |a (NLM)36961331 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jagtap, Kshitij |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveys |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVE: Flares of autoimmune rheumatic diseases (AIRDs) following COVID-19 vaccination are a particular concern in vaccine-hesitant individuals. Therefore, we investigated the incidence, predictors and patterns of flares following vaccination in individuals living with AIRDs, using global COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveys | ||
| 520 | |a METHODS: The COVAD surveys were used to extract data on flare demographics, comorbidities, COVID-19 history, and vaccination details for patients with AIRDs. Flares following vaccination were identified as patient-reported (a), increased immunosuppression (b), clinical exacerbations (c) and worsening of PROMIS scores (d). We studied flare characteristics and used regression models to differentiate flares among various AIRDs | ||
| 520 | |a RESULTS: Of 15 165 total responses, the incidence of flares in 3453 patients with AIRDs was 11.3%, 14.8%, 9.5% and 26.7% by definitions a-d, respectively. There was moderate agreement between patient-reported and immunosuppression-defined flares (K = 0.403, P = 0.022). Arthritis (61.6%) and fatigue (58.8%) were the most commonly reported symptoms. Self-reported flares were associated with higher comorbidities (P = 0.013), mental health disorders (MHDs) (P < 0.001) and autoimmune disease multimorbidity (AIDm) (P < 0.001).In regression analysis, the presence of AIDm [odds ratio (OR) = 1.4; 95% CI: 1.1, 1.7; P = 0.003), or a MHD (OR = 1.7; 95% CI: 1.1, 2.6; P = 0.007), or being a Moderna vaccine recipient (OR = 1.5; 95% CI: 1.09, 2.2; P = 0.014) were predictors of flares. Use of MMF (OR = 0.5; 95% CI: 0.3, 0.8; P = 0.009) and glucocorticoids (OR = 0.6; 95% CI: 0.5, 0.8; P = 0.003) were protective.A higher frequency of patients with AIRDs reported overall active disease post-vaccination compared with before vaccination (OR = 1.3; 95% CI: 1.1, 1.5; P < 0.001) | ||
| 520 | |a CONCLUSION: Flares occur in nearly 1 in 10 individuals with AIRDs after COVID vaccination; people with comorbidities (especially AIDm), MHDs and those receiving the Moderna vaccine are particularly vulnerable. Future avenues include exploring flare profiles and optimizing vaccine strategies for this group | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a autoimmunity | |
| 650 | 4 | |a flares | |
| 650 | 4 | |a rheumatic | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a vaccination hesitancy | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Naveen, R |e verfasserin |4 aut | |
| 700 | 1 | |a Day, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Sen, Parikshit |e verfasserin |4 aut | |
| 700 | 1 | |a Vaidya, Binit |e verfasserin |4 aut | |
| 700 | 1 | |a Nune, Arvind |e verfasserin |4 aut | |
| 700 | 1 | |a Nikiphorou, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Ai Lyn |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Vishwesh |e verfasserin |4 aut | |
| 700 | 1 | |a Saha, Sreoshy |e verfasserin |4 aut | |
| 700 | 1 | |a Shinjo, Samuel Katsuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ziade, Nelly |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Mrudula |e verfasserin |4 aut | |
| 700 | 1 | |a Velikova, Tsvetelina |e verfasserin |4 aut | |
| 700 | 1 | |a Milchert, Marcin |e verfasserin |4 aut | |
| 700 | 1 | |a Parodis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Edgar Gracia-Ramos, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Cavagna, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwana, Masataka |e verfasserin |4 aut | |
| 700 | 1 | |a Knitza, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Makol, Ashima |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Aarat |e verfasserin |4 aut | |
| 700 | 1 | |a Pauling, John D |e verfasserin |4 aut | |
| 700 | 1 | |a Wincup, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Barman, Bhupen |e verfasserin |4 aut | |
| 700 | 1 | |a Zamora Tehozol, Erick Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas Serrano, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a García-De La Torre, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Colunga-Pedraza, Iris J |e verfasserin |4 aut | |
| 700 | 1 | |a Merayo-Chalico, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Chibuzo, Okwara Celestine |e verfasserin |4 aut | |
| 700 | 1 | |a Katchamart, Wanruchada |e verfasserin |4 aut | |
| 700 | 1 | |a Goo, Phonpen Akawatcharangura |e verfasserin |4 aut | |
| 700 | 1 | |a Shumnalieva, Russka |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yi-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Hoff, Leonardo Santos |e verfasserin |4 aut | |
| 700 | 1 | |a El Kibbi, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Halabi, Hussein |e verfasserin |4 aut | |
| 700 | 1 | |a Sazliyana Shaharir, Syahrul |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, A T M Tanveer |e verfasserin |4 aut | |
| 700 | 1 | |a Dey, Dzifa |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez, Carlos Enrique Toro |e verfasserin |4 aut | |
| 700 | 1 | |a Caballero-Uribe, Carlo Vinicio |e verfasserin |4 aut | |
| 700 | 1 | |a Lilleker, James B |e verfasserin |4 aut | |
| 700 | 1 | |a Salim, Babur |e verfasserin |4 aut | |
| 700 | 1 | |a Gheita, Tamer |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Tulika |e verfasserin |4 aut | |
| 700 | 1 | |a Saavedra, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Distler, Oliver |e verfasserin |4 aut | |
| 700 | 0 | |a COVAD Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Chinoy, Hector |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Vikas |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Latika |e verfasserin |4 aut | |
| 700 | 1 | |a Griger, Zoltán |e investigator |4 oth | |
| 700 | 1 | |a Kardes, Sinan |e investigator |4 oth | |
| 700 | 1 | |a Andreoli, Laura |e investigator |4 oth | |
| 700 | 1 | |a Lini, Daniele |e investigator |4 oth | |
| 700 | 1 | |a Schreiber, Karen |e investigator |4 oth | |
| 700 | 1 | |a Vince, Melinda Nagy |e investigator |4 oth | |
| 700 | 1 | |a Singh, Yogesh Preet |e investigator |4 oth | |
| 700 | 1 | |a Ranjan, Rajiv |e investigator |4 oth | |
| 700 | 1 | |a Jain, Avinash |e investigator |4 oth | |
| 700 | 1 | |a Pandya, Sapan C |e investigator |4 oth | |
| 700 | 1 | |a Pilania, Rakesh Kumar |e investigator |4 oth | |
| 700 | 1 | |a Sharma, Aman |e investigator |4 oth | |
| 700 | 1 | |a Manesh Manoj, M |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Vikas |e investigator |4 oth | |
| 700 | 1 | |a Kavadichanda, Chengappa G |e investigator |4 oth | |
| 700 | 1 | |a Patro, Pradeepta Sekhar |e investigator |4 oth | |
| 700 | 1 | |a Ajmani, Sajal |e investigator |4 oth | |
| 700 | 1 | |a Phatak, Sanat |e investigator |4 oth | |
| 700 | 1 | |a Goswami, Rudra Prosad |e investigator |4 oth | |
| 700 | 1 | |a Chowdhury, Abhra Chandra |e investigator |4 oth | |
| 700 | 1 | |a Mathew, Ashish Jacob |e investigator |4 oth | |
| 700 | 1 | |a Shenoy, Padnamabha |e investigator |4 oth | |
| 700 | 1 | |a Asranna, Ajay |e investigator |4 oth | |
| 700 | 1 | |a Bommakanti, Keerthi Talari |e investigator |4 oth | |
| 700 | 1 | |a Shukla, Anuj |e investigator |4 oth | |
| 700 | 1 | |a Pande, Arunkumar R |e investigator |4 oth | |
| 700 | 1 | |a Chandwar, Kunal |e investigator |4 oth | |
| 700 | 1 | |a Ghodke, Akanksha |e investigator |4 oth | |
| 700 | 1 | |a Boro, Hiya |e investigator |4 oth | |
| 700 | 1 | |a Fazal, Zoha Zahid |e investigator |4 oth | |
| 700 | 1 | |a Cansu, Döndü Üsküdar |e investigator |4 oth | |
| 700 | 1 | |a Yıldırım, Reşit |e investigator |4 oth | |
| 700 | 1 | |a Gasparyan, Armen Yuri |e investigator |4 oth | |
| 700 | 1 | |a Del Papa, Nicoletta |e investigator |4 oth | |
| 700 | 1 | |a Sambataro, Gianluca |e investigator |4 oth | |
| 700 | 1 | |a Fabiola, Atzeni |e investigator |4 oth | |
| 700 | 1 | |a Govoni, Marcello |e investigator |4 oth | |
| 700 | 1 | |a Parisi, Simone |e investigator |4 oth | |
| 700 | 1 | |a Bocci, Elena Bartoloni |e investigator |4 oth | |
| 700 | 1 | |a Sebastiani, Gian Domenico |e investigator |4 oth | |
| 700 | 1 | |a Fusaro, Enrico |e investigator |4 oth | |
| 700 | 1 | |a Sebastiani, Marco |e investigator |4 oth | |
| 700 | 1 | |a Quartuccio, Luca |e investigator |4 oth | |
| 700 | 1 | |a Franceschini, Franco |e investigator |4 oth | |
| 700 | 1 | |a Sainaghi, Pier Paolo |e investigator |4 oth | |
| 700 | 1 | |a Orsolini, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a De Angelis, Rossella |e investigator |4 oth | |
| 700 | 1 | |a Danielli, Maria Giovanna |e investigator |4 oth | |
| 700 | 1 | |a Venerito, Vincenzo |e investigator |4 oth | |
| 700 | 1 | |a Grignaschi, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Giollo, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Alluno, Alessia |e investigator |4 oth | |
| 700 | 1 | |a Ioannone, Florenzo |e investigator |4 oth | |
| 700 | 1 | |a Fornaro, Marco |e investigator |4 oth | |
| 700 | 1 | |a Traboco, Lisa S |e investigator |4 oth | |
| 700 | 1 | |a Wibowo, Suryo Anggoro Kusumo |e investigator |4 oth | |
| 700 | 1 | |a Loarce-Martos, Jesús |e investigator |4 oth | |
| 700 | 1 | |a Prieto-González, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Raquel Aranega |e investigator |4 oth | |
| 700 | 1 | |a Yoshida, Akira |e investigator |4 oth | |
| 700 | 1 | |a Nakashima, Ran |e investigator |4 oth | |
| 700 | 1 | |a Sato, Shinji |e investigator |4 oth | |
| 700 | 1 | |a Kimura, Naoki |e investigator |4 oth | |
| 700 | 1 | |a Kaneko, Yuko |e investigator |4 oth | |
| 700 | 1 | |a Gono, Takahisa |e investigator |4 oth | |
| 700 | 1 | |a Tomaras, Stylianos |e investigator |4 oth | |
| 700 | 1 | |a Proft, Fabian Nikolai |e investigator |4 oth | |
| 700 | 1 | |a Holzer, Marie-Therese |e investigator |4 oth | |
| 700 | 1 | |a Gromova, Margarita Aleksandrovna |e investigator |4 oth | |
| 700 | 1 | |a Aharonov, Or |e investigator |4 oth | |
| 700 | 1 | |a Griger, Zoltán |e investigator |4 oth | |
| 700 | 1 | |a Hmamouchi, Ihsane |e investigator |4 oth | |
| 700 | 1 | |a El Bouchti, Imane |e investigator |4 oth | |
| 700 | 1 | |a Baba, Zineb |e investigator |4 oth | |
| 700 | 1 | |a Giannini, Margherita |e investigator |4 oth | |
| 700 | 1 | |a Maurier, François |e investigator |4 oth | |
| 700 | 1 | |a Campagne, Julien |e investigator |4 oth | |
| 700 | 1 | |a Meyer, Alain |e investigator |4 oth | |
| 700 | 1 | |a Langguth, Daman |e investigator |4 oth | |
| 700 | 1 | |a Limaye, Vidya |e investigator |4 oth | |
| 700 | 1 | |a Needham, Merrilee |e investigator |4 oth | |
| 700 | 1 | |a Srivastav, Nilesh |e investigator |4 oth | |
| 700 | 1 | |a Hudson, Marie |e investigator |4 oth | |
| 700 | 1 | |a Landon-Cardinal, Océane |e investigator |4 oth | |
| 700 | 1 | |a Zuleta, Wilmer Gerardo Rojas |e investigator |4 oth | |
| 700 | 1 | |a Arbeláez, Álvaro |e investigator |4 oth | |
| 700 | 1 | |a Cajas, Javier |e investigator |4 oth | |
| 700 | 1 | |a Silva, José António Pereira |e investigator |4 oth | |
| 700 | 1 | |a Fonseca, João Eurico |e investigator |4 oth | |
| 700 | 1 | |a Zimba, Olena |e investigator |4 oth | |
| 700 | 1 | |a Bohdana, Doskaliuk |e investigator |4 oth | |
| 700 | 1 | |a Ima-Edomwonyi, Uyi |e investigator |4 oth | |
| 700 | 1 | |a Dedeke, Ibukunoluwa |e investigator |4 oth | |
| 700 | 1 | |a Airenakho, Emorinken |e investigator |4 oth | |
| 700 | 1 | |a Madu, Nwankwo Henry |e investigator |4 oth | |
| 700 | 1 | |a Yerima, Abubakar |e investigator |4 oth | |
| 700 | 1 | |a Olaosebikan, Hakeem |e investigator |4 oth | |
| 700 | 1 | |a Becky, A |e investigator |4 oth | |
| 700 | 1 | |a Koussougbo, Oruma Devi |e investigator |4 oth | |
| 700 | 1 | |a Palalane, Elisa |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 62(2023), 12 vom: 01. Dez., Seite 3838-3848 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:3838-3848 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/kead144 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 12 |b 01 |c 12 |h 3838-3848 | ||